Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents

Abstract Background To report the switch rate of conventional immunosuppressive (CIS) therapies to the biological agents (BA) in patients with refractory Behcet’s uveitis (BU). Methods In this retrospective study, clinical records were reviewed of 76 patients’ 116 eyes presenting with BU who had bee...

Full description

Bibliographic Details
Main Authors: Hande Celiker, Haluk Kazokoglu, Haner Direskeneli
Format: Article
Language:English
Published: BMC 2018-10-01
Series:BMC Ophthalmology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12886-018-0929-5
_version_ 1817977097184870400
author Hande Celiker
Haluk Kazokoglu
Haner Direskeneli
author_facet Hande Celiker
Haluk Kazokoglu
Haner Direskeneli
author_sort Hande Celiker
collection DOAJ
description Abstract Background To report the switch rate of conventional immunosuppressive (CIS) therapies to the biological agents (BA) in patients with refractory Behcet’s uveitis (BU). Methods In this retrospective study, clinical records were reviewed of 76 patients’ 116 eyes presenting with BU who had been treated with immunosuppressive drug therapy. Mann Whitney U test was used for the intergroup comparisons of parameters without normal distribution as well as calculation of descriptive statistical methods (mean, standard deviation, median, frequency and rate). Wilcoxon Signed Ranks test was used for the intragroup comparisons of parameters without normal distribution. Pearson’s Chi-Square test and Fisher-Freeman-Halton test were used for the comparisons of qualitative data. Results Except for one, all patients were first treated with CIS regimens for BU. Thirty-one patients (41.3%) who were unresponsive to CIS regimens were switched to IFNα2a therapy. After that, eight of these cases were switched to the anti-TNF-α treatments. The presence of initial ocular complications were found to be statistically higher in BA treated patients than the CIS treated cases (p < 0.001). Both in CIS treated and in BA treated cases, an increase in visual acuity (VA) was observed during the last examination compared to the initial examination and was significant (p < 0.001 and p = 0.018, respectively). Conclusions CIS treatment was found to be effective and safe, as suggested in the management guidelines for severe BU. Biological therapy was also found effective for the improvement of the VA. We observed that 58.7% of cases could be treated with strong immunosuppressive therapies, however, nearly half of the patients could have lost their VA if BAs were not existent. During the treatment course of severe cases with BU, classical therapy stage must still be protected as the first-line therapy due to the their reasonable activity and safety.
first_indexed 2024-04-13T22:11:49Z
format Article
id doaj.art-56b3b40227c8498ab36841fc6bcb7d5f
institution Directory Open Access Journal
issn 1471-2415
language English
last_indexed 2024-04-13T22:11:49Z
publishDate 2018-10-01
publisher BMC
record_format Article
series BMC Ophthalmology
spelling doaj.art-56b3b40227c8498ab36841fc6bcb7d5f2022-12-22T02:27:41ZengBMCBMC Ophthalmology1471-24152018-10-011811710.1186/s12886-018-0929-5Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agentsHande Celiker0Haluk Kazokoglu1Haner Direskeneli2Department of Ophthalmology, Marmara University School of MedicineDepartment of Ophthalmology, Marmara University School of MedicineDivision of Rheumatology, Marmara University School of Medicine Fevzi Çakmak MahAbstract Background To report the switch rate of conventional immunosuppressive (CIS) therapies to the biological agents (BA) in patients with refractory Behcet’s uveitis (BU). Methods In this retrospective study, clinical records were reviewed of 76 patients’ 116 eyes presenting with BU who had been treated with immunosuppressive drug therapy. Mann Whitney U test was used for the intergroup comparisons of parameters without normal distribution as well as calculation of descriptive statistical methods (mean, standard deviation, median, frequency and rate). Wilcoxon Signed Ranks test was used for the intragroup comparisons of parameters without normal distribution. Pearson’s Chi-Square test and Fisher-Freeman-Halton test were used for the comparisons of qualitative data. Results Except for one, all patients were first treated with CIS regimens for BU. Thirty-one patients (41.3%) who were unresponsive to CIS regimens were switched to IFNα2a therapy. After that, eight of these cases were switched to the anti-TNF-α treatments. The presence of initial ocular complications were found to be statistically higher in BA treated patients than the CIS treated cases (p < 0.001). Both in CIS treated and in BA treated cases, an increase in visual acuity (VA) was observed during the last examination compared to the initial examination and was significant (p < 0.001 and p = 0.018, respectively). Conclusions CIS treatment was found to be effective and safe, as suggested in the management guidelines for severe BU. Biological therapy was also found effective for the improvement of the VA. We observed that 58.7% of cases could be treated with strong immunosuppressive therapies, however, nearly half of the patients could have lost their VA if BAs were not existent. During the treatment course of severe cases with BU, classical therapy stage must still be protected as the first-line therapy due to the their reasonable activity and safety.http://link.springer.com/article/10.1186/s12886-018-0929-5Anti-TNF-α therapyBehçet’s uveitisImmunosuppressive therapyInterferon therapyUveitis
spellingShingle Hande Celiker
Haluk Kazokoglu
Haner Direskeneli
Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
BMC Ophthalmology
Anti-TNF-α therapy
Behçet’s uveitis
Immunosuppressive therapy
Interferon therapy
Uveitis
title Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
title_full Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
title_fullStr Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
title_full_unstemmed Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
title_short Conventional immunosuppressive therapy in severe Behcet’s Uveitis: the switch rate to the biological agents
title_sort conventional immunosuppressive therapy in severe behcet s uveitis the switch rate to the biological agents
topic Anti-TNF-α therapy
Behçet’s uveitis
Immunosuppressive therapy
Interferon therapy
Uveitis
url http://link.springer.com/article/10.1186/s12886-018-0929-5
work_keys_str_mv AT handeceliker conventionalimmunosuppressivetherapyinseverebehcetsuveitistheswitchratetothebiologicalagents
AT halukkazokoglu conventionalimmunosuppressivetherapyinseverebehcetsuveitistheswitchratetothebiologicalagents
AT hanerdireskeneli conventionalimmunosuppressivetherapyinseverebehcetsuveitistheswitchratetothebiologicalagents